NIH Trials Registry Growing Quickly; Global Standards Up For Discussion
Executive Summary
The federal clinical trials registry is growing at a 20 to 40 percent faster clip as a result of the FDA Amendments Act provision expanding the universe of trials subject to public listing requirements
You may also be interested in...
PhRMA Clinical Trial Code: Disclosure Edition
The Pharmaceutical Research and Manufacturers of America is committing its members to disclose a broader array of clinical trials as a means to defend the corporate-sponsored clinical development process against continuing charges of bias and against the erosion of public trust
PhRMA Clinical Trial Code: Disclosure Edition
The Pharmaceutical Research and Manufacturers of America is committing its members to disclose a broader array of clinical trials as a means to defend the corporate-sponsored clinical development process against continuing charges of bias and against the erosion of public trust
Pharma Firms Want Protection From FDA Actions When Listing On ClinicalTrials.Gov
Pharmaceutical manufacturers are seeking assurances from FDA that information about clinical studies posted on clinicaltrials.gov will not expose them to charges of promoting products for unapproved uses